let-7, initially increased by chemotherapeutic treatments, can decrease de novo because of tumour acquired resistance following, for example, irradiation or cisplatin therapy that likely increases EZH2 in human non-small cancer lung cells (NSCLCs) [68]. Here, EZH2 is linked to neoplasm.